Post by Syntegon

Syntegon posts record year 2025 and aims for further growth. Sales: €1.75 bn, +10% Pharma sales: growth of 22% EBITDA: €282 m, +27% Free cash flow: €196 m, +51% In 2025, our positioning as a leading strategic lifecycle partner for our customers led to accelerated growth and value creation. Through a series of significant innovations and customer wins, we further expanded our global market leadership. In the structurally growing pharma sector, Syntegon achieved sales growth of 22%. Operating margins improved across our businesses, driven by the disciplined execution of our operational excellence initiatives. With an order intake of €1.86 bn, Syntegon has set the course for another year of substantial growth in 2026. Please click here to read the media release: https://lnkd.in/dJntwN5f #COCREATE #COSUCCEED #Syntegon #LifecyclePartner